Partnerships & Collaborations
ImmuPharma works actively with partners and collaborators within both industry and academia to support its business strategy and to achieve the Company’s goals.
ImmuPharma and US Avion Pharmaceuticals signed an exclusive license and development agreement for LupuzorTM to fund a new international Phase 3 trial.
The current terms of that agreement are:
- P140 LupuzorTM study funded up to $25m
- Milestones up to $70m & tiered double-digit royalties up to 17%
- Avion Pharmaceuticals has the exclusive rights for the commercialisation of LupuzorTM in the US
- ImmuPharma retains all the rights to commercialise LupuzorTM
outside of the US
Avion Pharmaceuticals also has the right to explore clinical development for other auto-immune indications within US territories.
Professor Sylviane Muller
Inventor of Lupuzor™ and P140 technology
Professor Muller earned her doctorate in sciences at the University of Strasbourg (France) and focused on immune responses as a postdoctoral researcher at the Max Planck Institute for Immunobiology in Freiburg (Germany). She is Professor at the Institute of Advanced Studies of the Strasbourg University where she holds the chair in Therapeutic immunology; emeritus Research Director at the Centre National de la Recherche Scientifique; former Director of the CNRS Unit Immunopathology and therapeutic chemistry (2001-2017) and…Read more..
Europe’s largest fundamental research institution and ImmuPharma’s long standing collaboration partner.
ImmuPharma’s low risk-strategy is to capitalise on pioneering research taking place primarily at Europe’s largest fundamental research institution, the Centre National de la Recherche Scientifique (National Center for Scientific Research) or CNRS. The CNRS was founded in 1939 and is a government-funded research organisation, under the administrative authority of France’s Ministry of Research and has over…Read more..
Orano is a leading international group and a key player in the nuclear energy sector. With 17,000 employees worldwide, the group is committed to meeting the world’s energy challenges on a daily basis, by helping deliver plentiful, safe, low-carbon and competitive electricity.
Imperial is a global top ten university with a world-class reputation in science, engineering, business and medicine.